Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 11:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 42 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: 5% Lidocaine Patch Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Nanocytology Test to Evaluate Skin Cancer in High Risk Patients

NCT01905891
View directory record Official record
Conditions
Actinic Keratosis, Squamous Cell Carcinoma
Interventions
Superficial shave biopsy
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 18, 2014 · Synced Sep 26, 2026, 11:19 AM EDT
Completed Phase 4 Interventional Results available

Bacteriostatic Saline as a Local Anesthetic in Minor Eyelid Procedures

NCT05294640
View directory record Official record
Conditions
Eyelid Tumor, Eyelid Bump, Eyelid Deformity, Eyelid Abscess, Eyelid Boil, Eyelid Papilloma, Anesthesia, Local, Ophthalmology
Interventions
0.9% Bacteriostatic Local Anesthetic Injection, 1% Lidocaine with 1:100,000 epinephrine Local Anesthetic Injection, Eyelid Lesion Removal
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 110 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Sep 26, 2026, 11:19 AM EDT
Completed Not applicable Interventional Results available

Lidocaine 5% Patch (Lidoderm) for the Prevention of Acute and Chest Pain Following Robotic Valve Surgery

NCT03120351
View directory record Official record
Conditions
Perioperative Chest Pain
Interventions
Lidoderm 5 % Topical Patch, Placebo patch
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Sep 26, 2026, 11:19 AM EDT
Terminated Phase 4 Interventional

Lidocaine Patch 5% Versus Celecoxib 200 mg in Chronic Axial Low Back Pain

NCT00904397
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Lidoderm®, Celecoxib
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
21
States / cities
Northport, Alabama • Phoenix, Arizona • Beverly Hills, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2010 · Synced Sep 26, 2026, 11:19 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Post-Op Lidocaine Patch

NCT03500211
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Lidoderm 5 % Topical Patch, Sham Topical Patch
Drug · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Sep 26, 2026, 11:19 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of the Lidoderm Patch Applied to Patients With Osteoarthritis of the Knee

NCT00589979
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
Lidoderm (Lidocaine 5% Patch), Placebo Patch
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
37 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
20
States / cities
Paradise Valley, Arizona • Phoenix, Arizona • Milford, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 26, 2026, 11:19 AM EDT
Recruiting Phase 4 Interventional

Frozen Shoulder and Hormone Replacement Therapy

NCT07278323
View directory record Official record
Conditions
Adhesive Capsulitis of the Shoulder, Frozen Shoulder
Interventions
Hormone Replacement Therapy (HRT), Corticosteroid and 1%lidocain, physical therapy
Drug · Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 26, 2026, 11:19 AM EDT
Completed Phase 4 Interventional

A Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain

NCT00904020
View directory record Official record
Conditions
Postherpetic Neuralgia, Diabetic Neuropathy, Low Back Pain
Interventions
Lidoderm
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
11
States / cities
Birmingham, Alabama • Phoenix, Arizona • Plantation, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Sep 26, 2026, 11:19 AM EDT
Terminated Phase 4 Interventional Results available

Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple Sclerosis

NCT00414453
View directory record Official record
Conditions
Neuropathic Pain, Chronic Pain, Multiple Sclerosis
Interventions
Lidocaine patch 5%, Extended-release oxycodone, Placebo extended-release oxycodone pills, Placebo lidocaine patches
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2015 · Synced Sep 26, 2026, 11:19 AM EDT
Completed Phase 2 Interventional

Pilot Study of Lidocaine 5% Patch Versus Placebo in Patients With Osteoarthritis Pain of the Knee

NCT00904462
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Lidoderm, Placebo patch
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
24
States / cities
Birmingham, Alabama • Hueytown, Alabama • Tallassee, Alabama + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2010 · Synced Sep 26, 2026, 11:19 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

A Prospective Pilot Study of a Non-Narcotic Post-Operative Course After Colectomy

NCT05200806
View directory record Official record
Conditions
Analgesia, Post-Operative Pain, Breakthrough Pain, Colectomy
Interventions
Non-Narcotic ERAS Post-Operative Pain Management
Other
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Sep 26, 2026, 11:19 AM EDT
Terminated Phase 4 Interventional Results available

Conventional vs Bipolar SIJ RFA for Treatment of Sacroiliac Joint Pain

NCT05409443
View directory record Official record
Conditions
Sacroiliac Joint Complex, Low Back Pain
Interventions
Nimbus Sacroiliac Joint Radiofrequency Ablation (N-SIJRFA), Conventional Sacroiliac Joint Radiofrequency Ablation (C-SIJRFA)
Procedure
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Farmington, Utah • Salt Lake City, Utah • South Jordan, Utah
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 26, 2026, 11:19 AM EDT
Completed Phase 4 Interventional

Pilot Study of the Efficacy and Safety of Lidoderm Patch in the Treatment of Low Back Pain

NCT00904475
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Lidoderm®
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
6
States / cities
Birmingham, Alabama • Hueytown, Alabama • Phoenix, Arizona + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2010 · Synced Sep 26, 2026, 11:19 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Brain Imaging of Lidoderm for Chronic Back Pain

NCT01515540
View directory record Official record
Conditions
Low Back Pain
Interventions
lidocaine, placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 29, 2013 · Synced Sep 26, 2026, 11:19 AM EDT
Terminated Phase 4 Interventional

Lidocaine Patch Versus Celecoxib in Pain From Osteoarthritis of the Knee

NCT00904605
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
Lidoderm, Celecoxib
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
20
States / cities
Hueytown, Alabama • Mesa, Arizona • Oro Valley, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2010 · Synced Sep 26, 2026, 11:19 AM EDT
Completed Phase 4 Interventional

A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions

NCT00904202
View directory record Official record
Conditions
Postherpetic Neuralgia, Diabetic Neuropathy, Complex Regional Pain Syndrome, Carpal Tunnel Syndrome, HIV Neuropathy, Idiopathic Sensory Neuropathy, Peripheral Neuropathy
Interventions
Placebo Capsules + Placebo Patch, Placebo capsules + Lidoderm®, Gabapentin + Placebo, Gabapentin + Lidoderm®, Gabapentin 300 mg capsules 1800 mg/day + placebo patch, Gabapentin 1800 mg/day + Lidoderm patch
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
7
States / cities
Birmingham, Alabama • Hueytown, Alabama • Phoenix, Arizona + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Sep 26, 2026, 11:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Adhesion Performance Study of Lidocaine Topical System 1.8% Compared to Lidocaine Patch 5% and Lidocaine Medicated Plaster 5% in Healthy, Adult, Human Subjects

NCT04320173
View directory record Official record
Conditions
Healthy
Interventions
Lidocaine patch 1.8%, Lidocaine patch 5%, Lidocaine medicated plaster 5%
Drug
Lead sponsor
Scilex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Sep 26, 2026, 11:19 AM EDT
Completed Phase 2 Interventional Results available

Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)

NCT00499083
View directory record Official record
Conditions
Breast Cancer
Interventions
therapeutic autologous dendritic cells, aromatase inhibition therapy, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, gene expression analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, adjuvant therapy, biopsy, conventional surgery, neoadjuvant therapy, radiation therapy
Biological · Drug · Genetic + 3 more
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Tampa, Florida • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Sep 26, 2026, 11:19 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Use of Topical Lidocaine to Reduce Pain in Patients With Diabetic Neuropathy

NCT01086150
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
Skin biopsy, Lidocaine 5% patches
Procedure · Drug
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years to 70 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Sep 26, 2026, 11:19 AM EDT
Completed Early Phase 1 Interventional

Commercial Lidocaine Patch as a Treatment for Ear-ringing

NCT02088866
View directory record Official record
Conditions
Tinnitus
Interventions
Transdermal Lidocaine
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 26, 2026, 11:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

CO2 Laser vs Lidocaine for Vestibulodynia in Premenopausal Women

NCT05336825
View directory record Official record
Conditions
Vulvodynia
Interventions
CO2 laser, Lidocaine patch 5%
Device · Drug
Lead sponsor
Atlantic Health System
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Denville, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Sep 26, 2026, 11:19 AM EDT
Not yet recruiting Phase 4 Interventional

Modality Choice Before and After Failure for the Treatment of Painful Diabetic Neuropathy

NCT07795593
View directory record Official record
Conditions
Painful Diabetic Neuropathy (PDN), Diabetic Nephropathies
Interventions
Cognitive Behavioral Therapy (CBT), Oral Medication, Topical Medication
Device · Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
23
States / cities
Stanford, California • Jacksonville, Florida • Chicago, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 26, 2026, 11:19 AM EDT
Completed Phase 4 Interventional Results available

MAST Trial: Multi-modal Analgesic Strategies in Trauma

NCT03472469
View directory record Official record
Conditions
Nonspecific Pain Post Traumatic Injury
Interventions
Acetaminophen IV/PO, Acetaminophen PO, Ketorolac, Celebrex, Naproxen, Tramadol, Pregabalin, Gabapentin, Lidocaine, Opioids, Regional anesthesia
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
16 Years and older
Enrollment
1,561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced Sep 26, 2026, 11:19 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Therapeutic Epidural Patch Versus Pain Block in the Midface for Headache

NCT03112720
View directory record Official record
Conditions
Postdural Puncture Headache
Interventions
Epidural Blood Patch, Sphenopalatine Ganglion Block
Device · Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
13 Years to 92 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
2
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 26, 2026, 11:19 AM EDT